Bodhi Tree Biotechnology Inc
Key Highlights
- Fiscal year ended September 30, 2025, with 25,441,042 shares of common stock outstanding as of December 29, 2025.
- The company's common stock is not publicly traded.
- Classified as a 'smaller reporting company' and 'emerging growth company' by the SEC.
Financial Analysis
Bodhi Tree Biotechnology Inc Annual Report - How They Did This Year
Alright, let's dive into Bodhi Tree Biotechnology Inc.'s performance for the fiscal year that wrapped up on September 30, 2025.
A Quick Look at the Company Bodhi Tree Biotechnology Inc. is a company incorporated in Delaware, with its main office located at 4125 Blackhawk Plaza Circle, Suite 172, Danville, CA 94506. Leading the charge is Xiaohang Wang, who serves as the CEO, President, Treasurer, and a Director, with Yun Xia as the Secretary.
Your Investment Snapshot As of December 29, 2025, the company had 25,441,042 shares of Common Stock outstanding. As of the last business day of their second fiscal quarter, there wasn't a public market where you could buy or sell their common stock. This means it's not currently traded on an exchange like the NYSE or Nasdaq.
The company is classified as a "smaller reporting company" and an "emerging growth company" by the SEC. They have also chosen to use the extended transition period for new accounting standards.
What Could Affect Bodhi Tree's Future? (Risks to Keep in Mind) The company highlighted several factors that could impact its future performance:
- Staying in Business: There's a concern about their ability to continue operating as a "going concern."
- Funding: Getting the necessary financing to run their operations is a key challenge.
- Limited Operating History: They have a limited operating history.
- Talent Hunt: Finding and keeping skilled employees is crucial for a biotech company.
- Growing Pains: Managing any future growth effectively will be important.
- Product Development: Their ability to successfully research and develop new products is at the core of their business.
- Partnerships: Successfully completing potential acquisitions and working with other companies (collaborations) are also factors that could affect their path forward.
Key Takeaways for Investors: Bodhi Tree Biotechnology Inc. concluded its fiscal year on September 30, 2025, with 25,441,042 shares of common stock outstanding as of December 29, 2025. The company's stock is not publicly traded. As a "smaller reporting company" and "emerging growth company," it operates with certain reporting flexibilities. The company has identified several key risks, including its ability to continue as a "going concern," securing necessary funding, its limited operating history, talent acquisition and retention, managing growth, successful product development, and effective partnerships.
Risk Factors
- Concerns about ability to continue as a 'going concern' and secure necessary financing.
- Limited operating history and challenges in talent acquisition and retention.
- Risks associated with managing growth, successful product development, and effective partnerships.
Why This Matters
This annual report for Bodhi Tree Biotechnology Inc. is crucial because it confirms the company's current status as a private entity, with its common stock not publicly traded. For investors, this means there's no immediate market liquidity, making any investment highly speculative and long-term oriented. The reported 25,441,042 shares outstanding provide a baseline for potential future valuation should the company ever pursue a public offering.
More critically, the filing highlights significant 'going concern' risks and challenges in securing necessary funding. This signals fundamental questions about the company's ability to sustain operations without substantial capital injections. Combined with a limited operating history, these factors indicate a high-risk profile, where the company's survival hinges on its success in overcoming these financial hurdles and proving its business model.
Furthermore, its classification as a 'smaller reporting company' and 'emerging growth company' means it benefits from reduced disclosure requirements, which can limit the transparency available to potential investors. While this offers flexibility to the company, it places a greater onus on investors to scrutinize the available information, particularly regarding product development, talent acquisition, and strategic partnerships, which are vital for a biotech's long-term viability.
What Usually Happens Next
Following this 10-K filing, which provides a retrospective view of the fiscal year ending September 30, 2025, the immediate focus for Bodhi Tree Biotechnology Inc. will be on executing strategies to address the significant risks identified. Since the company is not publicly traded, there won't be a direct stock market reaction. Instead, the 'next steps' are internal and strategic, centered on operational survival and growth.
Investors, particularly those considering private investment, should closely monitor for any announcements regarding successful funding rounds or strategic partnerships. Securing substantial capital is paramount to alleviating the 'going concern' risk and fueling product development, which is the core of any biotechnology company. Progress in research and development, potentially leading to clinical trials or regulatory milestones, would be critical indicators of future viability.
Additionally, watch for news on key executive hires or scientific talent acquisition, as a strong team is essential for navigating the complex biotech landscape. Any indication of a path towards a public listing, such as an initial public offering (IPO) or direct listing, would represent a major milestone, but this would likely only occur after the company has demonstrated significant progress in addressing its funding and operational challenges.
Learn More
Document Information
SEC Filing
View Original DocumentAnalysis Processed
December 30, 2025 at 08:52 AM
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.